Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

Summary

This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group, dose-ranging study, conducted in subjects with moderate-to-severe atopic dermatitis.

Timeline

Start

2021-09-30

Primary completion

2023-05-17

Completion

2023-05-17

Outcome

Outcome not reported

Stopped (Business): “Clinical study and development strategy adjustment”

Drugs

Indications